3rd Li Ka Shing Institute of Virology Symposium is held in the University of Alberta (Edmonton, Canada)
KMT Hepatech, Inc. is proud to sponsor 3rd Li Ka Shing Institute of Virology Symposium
“Alberta Virology Conference”, which is held at the University of Alberta on June 1 and 2, 2017.
The goal of the conference is to bring together the vast virological expertise that exists in Alberta (Canada) and showcase the exciting work that is being done locally. The very first session at the conference was devoted to great extent to hepatitis research. Presentations of leading edge researchers in this field provided great coverage of history and the present state of hepatitis B and C.
Dr. Michael Houghton
, who along with colleagues discovered HCV in 1989 and developed global HCV blood tests as well as identified key viral targets for drug development, summarized current stage of vaccine development against Hepatitis C (HCV).
Dr. Lorne Tyrrell
, one of the discoverers of lamivudine – the first oral antiviral therapy for HBV, reviewed the studies in hepatitis B and C, mentioning the importance of KMT Mouse model for the development of HCV treatment.
Dr. Carla Coffin
(University of Calgary) in her presentation focused on chronic and occult hepatitis B virus (HBV) persistence in the context of non-alcoholic fatty liver disease (NAFLD), pregnancy, liver transplantation, and co-infection with HIV.
Further details can be found on the Alberta Virology Conference website